Militia Capital Management LLC Buys New Holdings in Harrow, Inc. $HROW

Militia Capital Management LLC purchased a new position in Harrow, Inc. (NASDAQ:HROW) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 23,519 shares of the company’s stock, valued at approximately $829,000. Militia Capital Management LLC owned 0.06% of Harrow at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HROW. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Harrow in the 4th quarter valued at $26,000. KBC Group NV purchased a new position in shares of Harrow during the first quarter worth $31,000. Raymond James Financial Inc. acquired a new position in Harrow during the second quarter valued at $48,000. SBI Securities Co. Ltd. lifted its position in Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after purchasing an additional 846 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after purchasing an additional 369 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $38.77 on Monday. The company’s fifty day moving average price is $39.81 and its 200 day moving average price is $40.36. Harrow, Inc. has a 1 year low of $28.54 and a 1 year high of $54.85. The company has a market capitalization of $1.45 billion, a PE ratio of -94.56 and a beta of 0.26. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.30 and a current ratio of 2.48.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same period in the previous year, the firm posted ($0.38) EPS. On average, research analysts predict that Harrow, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on HROW. B. Riley Financial reaffirmed a “buy” rating and set a $65.00 price target (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Cantor Fitzgerald lowered their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. BTIG Research reaffirmed a “buy” rating and set a $63.00 target price on shares of Harrow in a report on Tuesday, July 21st. Finally, Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $69.43.

Insider Transactions at Harrow

In other Harrow news, Director Adrienne L. Graves bought 1,000 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were purchased at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the transaction, the director directly owned 1,000 shares of the company’s stock, valued at approximately $31,070. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew R. Boll purchased 3,500 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was acquired at an average price of $29.90 per share, with a total value of $104,650.00. Following the purchase, the chief financial officer owned 814,679 shares in the company, valued at $24,358,902.10. This represents a 0.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.80% of the stock is owned by company insiders.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.